Polymyositis and dermatomyositis pathophysiology

Jump to navigation Jump to search

Polymyositis and dermatomyositis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyositis and dermatomyositis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyositis and dermatomyositis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyositis and dermatomyositis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyositis and dermatomyositis pathophysiology

CDC on Polymyositis and dermatomyositis pathophysiology

Polymyositis and dermatomyositis pathophysiology in the news

Blogs on Polymyositis and dermatomyositis pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Polymyositis and dermatomyositis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

The exact pathogenesis of polymyositis and dermatomyositis is not fully understood. However, it is understood that polymyositis and dermatomyositis are the result of autoimmune attack but triggering factors are not well-known. Polymyositis is caused by inflammation and degeneration of the muscles. In polymyositis, CD8-positive cytotoxic T cells invade muscle fibers that express MHC class I antigens which may leads to fiber necrosis via the perforin pathway. Hypoxia may reduce creatine phosphate and adenosine triphosphate (ATP) levels in muscle and lead to fatigue and muscle weakness. Dermatomyositis is caused by skin inflammation. In dermatomyositis, activation and deposition of complements may lead to lysis of endomysial capillaries and muscle ischemia. Genes including HLA DRB1*0301 and HLA DQA1*0501 alleles, and tumour necrosis factor 308A might be associated with development of polymyositis and dermatomyositis, especially in familial cases. Different conditions associated with polymyositis and dermatomyositis include respiratory and cardiac diseases, other connective tissue diseases, and malignancies. On microscopic histopathological analysis, partial invasion of lymphocytes within the muscle fibers and regenerating fibers with enlarged nuclei are characteristic findings of polymyositis.

Pathophysiology

Pathogenesis

The exact pathogenesis of polymyositis and dermatomyositis is not fully understood. However, it is understood that polymyositis and dermatomyositis are the result of autoimmune attack but triggering factors are not well-known.[1][2][3][4][5]

Polymyositis

  • Polymyositis is caused by inflammation and degeneration of the muscles.
  • In polymyositis, CD8-positive cytotoxic T cells invade muscle fibers that express MHC class I antigens which may lead to fiber necrosis via the perforin pathway.
  • Hypoxia may reduce creatine phosphate and adenosine triphosphate (ATP) levels in muscle and lead to fatigue and muscle weakness.
  • Interleukin (IL) 21, tumor growth factor-b (TGF-b), and high-mobility group protein 1 (HMG-1) induce muscle fatigue by decreasing Ca release. 

Dermatomyositis

  • Dermatomyositis is caused by skin inflammation.[6][7][8][9]
  • In dermatomyositis, activation and deposition of complements may lead to lysis of endomysial capillaries and muscle ischemia.[4]

Genetics

  • Genes might be associated with development of polymyositis and dermatomyositis, especially in familial cases, which include:[10]
    • HLA DRB1*0301 alleles for polymyositis and inclusion-body myositis
    • HLA DQA1*0501 for juvenile dermatomyositis,
    • Tumour necrosis factor 308A polymorphism for photosensitivity in dermatomyositis

Associated Conditions

Different conditions associated with polymyositis and dermatomyositis include:

Association Polymyositis Dermatomyositis
Malignancy 5-7 fold more risks than the general population

Microscopic Pathology

  • On microscopic histopathological analysis of polymyositis, partial invasion of lymphocytes within the muscle fibers and regenerating fibers with enlarged nuclei are characteristic findings.
  • On microscopic histopathological analysis of dermatomyositis, perifascicular inflammation with perifascicular atrophy and loss of vessels around muscle fibers are characteristic findings.
Muscle biopsy frozen section specimen - Myositis (HE stain)-Partial invasion of lymphocytes within the muscle fibers via librepathology.org[11]
Muscle biopsy frozen section specimen - Myositis (CD45 stain) Partial invasion of lymphocytes within the muscle fibers via librepathology.org[12]
Immunostain in a case of dermatomyositis displaying complement complex depositis of C5b9 Via librepathology.org[13]


References

  1. Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
  2. Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
  3. Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
  4. 4.0 4.1 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
  5. Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
  6. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.
  7. Tiniakou E, Mammen AL (February 2017). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clin Rev Allergy Immunol. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. PMID 26429706.
  8. Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.
  9. Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
  10. Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
  11. "File:Neuropathology case XII 01.jpg - Libre Pathology".
  12. "File:Neuropathology case XII 03.jpg - Libre Pathology".
  13. "File:Dermatomyositis c5b9.jpg - Libre Pathology".